Arca
Skip to content
Tools
Tools

PTH1R: Parathyroid hormone/parathyroid hormone-related peptide receptor

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH).

  • Drugs that act on it: 6
  • Approved: 5
  • In phases 1 to 3: 1
  • Sponsors: 5

Who Is On It, and How Far Along

Every drug ChEMBL records acting on PTH1R, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide
  • Other

Approved5

  • Parathyroid hormone
  • Teriparatide
  • Teriparatide acetate
  • Abaloparatide
  • Palopegteriparatide

Phase 30

    Phase 21

    • Ostabolin-c

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Shenzhen Salubris Pharmaceuticals Co., Ltd.233%
      • Zelos Therapeutics117%

      Modalities

      Drugs on this target by ChEMBL molecule type.

      • Protein or peptide583%
      • Other117%

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Parathyroid hormone receptor agonist.
      Parathyroid hormoneApprovedTakeda Pharmaceuticals USAProtein or peptideAgonist—97Boxed warning
      TeriparatideApprovedShenzhen Salubris Pharmaceuticals Co., Ltd.Protein or peptideAgonist—16—
      Teriparatide acetateApprovedShenzhen Salubris Pharmaceuticals Co., Ltd.Protein or peptideAgonist—16—
      AbaloparatideApprovedRadius HealthProtein or peptideAgonist—7Boxed warning
      PalopegteriparatideApprovedAscendis PharmaProtein or peptideAgonist—6—
      Ostabolin-cPhase 2Zelos TherapeuticsOtherAgonist—0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 26 in all, from ClinicalTrials.gov.
      Treating PHPT With the nPulse™ Vybrance™ PE SystemParathyroid hormoneNot applicableNot yet recruitingPulse Biosciences, Inc.2026-11-03
      Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid AdenomasParathyroid hormoneEarly phase 1RecruitingUniversity of Pennsylvania2026-11-02
      Lenvatinib in Patients With Advanced Parathyroid CarcinomaParathyroid hormonePhase 2Not yet recruitingYonsei University2026-09-28
      Blood Parameter Changes Following Aerobic Exercise in Professional Soccer PlayersParathyroid hormoneNot applicableNot yet recruitingInonu University2026-09-17
      Hyperparathyroidism and Dialysis Adequacy in Hemodialysis PatientsParathyroid hormone—Not yet recruitingAssiut University2026-09-15
      Pistachio Consumption in Patients With Chronic Kidney DiseaseParathyroid hormoneNot applicableNot yet recruitingShahid Beheshti University of Medical Sciences2026-09-11
      NIRAF-camera Versus Conventional Surgery in Preoperative Imaging Negative Primary HyperparathyroidismParathyroid hormoneNot applicableRecruitingThe Cleveland Clinic2026-09-10
      A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term HypoparathyroidismPalopegteriparatidePhase 3RecruitingAscendis Pharma A/S2026-07-16
      Cardiovascular Effects of Parathyroid Hormone Analogues in Chronic HypoparathyroidismPalopegteriparatide, Parathyroid hormone—Active, not recruitingNational and Kapodistrian University of Athens2026-07-16
      MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal OsteoporosisAbaloparatideNot applicableRecruitingIstituto Auxologico Italiano2026-06-01
      The Effect of Osteoporotic Medications on Vertebral Bone Quality ScoreAbaloparatidePhase 2Enrolling by invitationState University of New York at Buffalo2026-05-14
      A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensTeriparatide, Teriparatide acetatePhase 2RecruitingShenzhen Salubris Pharmaceuticals Co., Ltd.2026-05-12
      A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and BreastfeedingPalopegteriparatide—RecruitingAscendis Pharma A/S2026-01-15
      A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)Palopegteriparatide—RecruitingAscendis Pharma A/S2025-12-04
      Translation and Validation of the Hypoparathyroidism Patient Experience Scales (HPES) Questionnaire in GreekPalopegteriparatide—Not yet recruitingAristotle University Of Thessaloniki2025-09-08
      A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With HypoparathyroidismPalopegteriparatidePhase 3RecruitingAscendis Pharma Bone Diseases A/S2025-07-24
      Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal OsteoporosisTeriparatide, Teriparatide acetateNot applicableNot yet recruitingPeking University Third Hospital2025-04-30
      To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of FractureAbaloparatide, Teriparatide, Teriparatide acetatePhase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.2025-03-27
      Relationship Between Thoracic Hyperkyphosis and Fall Risk in Women with Fragility Vertebral FracturesTeriparatide, Teriparatide acetate—Active, not recruitingUniversity of Palermo2025-02-24
      A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult SubjectsAbaloparatidePhase 1Not yet recruitingThe Affiliated Hospital of Qingdao University2024-12-31
      Combined Anabolic TherapyTeriparatide, Teriparatide acetatePhase 4RecruitingMassachusetts General Hospital2024-08-16
      PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot)Teriparatide, Teriparatide acetatePhase 1 / Phase 2Not yet recruitingUniversity of Calgary2024-03-12
      Precision Medicine Approach for Osteoporosis - Follow Up StudyTeriparatide, Teriparatide acetatePhase 4Enrolling by invitationPaul F Netzel2024-02-20
      Sequential Therapies After Osteoanabolic TreatmentAbaloparatide, Teriparatide, Teriparatide acetate—Recruiting424 General Military Hospital2023-12-11
      Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab AloneAbaloparatidePhase 4Active, not recruitingHospital for Special Surgery, New York2020-07-13
      Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion SurgeryAbaloparatidePhase 2Active, not recruitingHospital for Special Surgery, New York2019-02-15

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Metaphyseal chondrodysplasia, Jansen type
      0.77
      Chondrodysplasia Blomstrand type
      0.76
      Primary failure of tooth eruption
      0.74
      Eiken syndrome
      0.71
      Abnormality of the skeletal system
      0.54
      Ollier disease
      0.38

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1793, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q03431, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.